Hormone Receptor Positive Her2 Negative Breast Cancer clinical trials

Explore recruiting hormone receptor positive her2 negative breast cancer clinical trials.

Recruiting hormone receptor positive her2 negative breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hormone Receptor Positive Her2 Negative Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

NeoAdjuvant PErsonalized therapy in Estrogen Receptor positive breast cancer (NAPEER) - An open label phase II trial of endocrine treatment with or without capivasertib, followed by response assessment before neoadjuvant chemotherapy with bevacizumab (if ViRP signature positive).

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

I3Y-MC-JPBL: MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without abemaciclib, a CDK4/6 Inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

Belgium, Poland, Italy, Spain, Greece

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Open-label, Randomized Study of Dato-DXd Versus Investigator’s Choice of Chemotherapy in Participants With Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Spain, France, Germany, Poland, Italy, Belgium +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Prevention of Ribociclib-related hepatotoxicity in breast cancer patients: a phase II, multicentre, open label, single arm trial of Silimarin.

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

C4391025_AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO LETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER IN THE NEOADJUVANT SETTING

Italy, Spain, France, Slovakia, Germany, Sweden +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Elacestrant and exemestane for patients with pretreated HR+/HER2- metastatic breast cancer and [18F]-FES-avid lesions (COMBINE): a proof-of-concept phase 2 clinical trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Hormone Receptor Positive Her2 Negative Breast Cancer trials by city

Hormone Receptor Positive Her2 Negative Breast Cancer in Toronto Hormone Receptor Positive Her2 Negative Breast Cancer in Vancouver Hormone Receptor Positive Her2 Negative Breast Cancer in Montreal Hormone Receptor Positive Her2 Negative Breast Cancer in Calgary Hormone Receptor Positive Her2 Negative Breast Cancer in Edmonton Hormone Receptor Positive Her2 Negative Breast Cancer in Ottawa Hormone Receptor Positive Her2 Negative Breast Cancer in Winnipeg Hormone Receptor Positive Her2 Negative Breast Cancer in Quebec City Hormone Receptor Positive Her2 Negative Breast Cancer in Hamilton Hormone Receptor Positive Her2 Negative Breast Cancer in Kitchener Hormone Receptor Positive Her2 Negative Breast Cancer in London Hormone Receptor Positive Her2 Negative Breast Cancer in Halifax Hormone Receptor Positive Her2 Negative Breast Cancer in New York Hormone Receptor Positive Her2 Negative Breast Cancer in Los Angeles Hormone Receptor Positive Her2 Negative Breast Cancer in Chicago Hormone Receptor Positive Her2 Negative Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease